" class="no-js "lang="en-US"> Bruno Larvol - Medtech Alert
Saturday, September 23, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Bruno Larvol

Bruno Larvol

About Bruno Larvol

Founder of LARVOL, a VR-first, remote-always organization of 170+ professionals providing SaaS solutions to 15 Fortune 500 healthcare and pharmaceutical companies. LARVOL aims to grow into the most interesting $100 M business.

Related Story

Diseases

 LARVOL Launches the First Cancer-Focused Social Listening Platform for Pharma and Oncology | Pharmtech Focus

LARVOL Launches Cancer-Focused Social Listening Platform

April 14 2021

LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today […]